Andrey Soares
@SoaresAndrey
Scientific Committee Member LACOG - GU | Medical Oncologist at Hospital Albert Einstein | Owner and founder BIO | Following or RT does not mean endorsement
ID:60448870
http://www.bioeducation.com.br 27-07-2009 01:24:52
4,5K Tweets
2,4K Followers
857 Following
For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano…
For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin…
The majority, at 70%, recommend imaging for response monitoring during 177Lu-PSMA treatment in the absence of clinical progression in most patients, indicating a consensus that regular imaging is crucial for effective treatment!
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin…
How to utilize presence or absence of CT findings on a PSMA PET/CT
Fantastic talk by prof. Stefano Fanti
☢️ 'WITH GREAT POWER COMES GREAT RESPONSIBILITY.'
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen…
Michael Hofman Alternative PSMA ligands for diagnostics & treatment:
Are they interchangeable? Outstanding overview!
☢️ Do they have similar safety & efficacy: radioequivalent
☢️ Precision medicine: patient selections is key
☢️ Please: don't treat blindly!
☢️ Best PSMA radiotracer…
Who should receive chemotherapy before PSMA radioligand therapy?
Clinically very relevant question!
M.R.Smith
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji…
Dosing of radioligand therapy in special situations and/or toxicity! L. Emmett
⭕️ Heterogeneity predicts toxicity and response!
⭕️Less data about delayed toxicity
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast!…
#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 How to select mCRPC pts #ProstateCancer for lutetium-177 RLT therapy ?👉excellent talk by Thomas Hope 👉select pts based on ⬆️uptake than liver, post-Rx SPECT (+conventional scans) & not PSMA-PET should be done to follow pts👇 OncoAlert PCF Science
Ken Herrmann on “PSMA radioligand therapy - state of the art”
☢️PSMA-Lu is here and more RLT to come! Tx Monitoring an important challenge
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James…
Prime time for PSMA at #APCCC24 !
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James Christopher Sweeney, MBBS GU Cast | Urology podcast! Joaquin Mateo LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji Neeraj Agarwal, MD, FASCO @uromigos…
A significant majority of respondents, 76%, do not let genetic evaluation results influence their first-line treatment decisions for metastatic hormone-sensitive prostate cancer (mHSPC) outside clinical trials, provided that testing is unrestricted.
#APCCC24 Advanced Prostate Cancer Consensus Conference…
The majority of responses indicate a preference for both germline and somatic genetic testing in patients with metastatic castration-resistant prostate cancer (mCRPC), which is done regardless of somatic findings.
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert…